title: Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day.
abstract: This dose-escalation study was performed to evaluate safety and efficacy of imiquimod 5% cream in the treatment of uncircumcised men with penile warts associated with the foreskin. The cream was applied 3 times/week (n=34) or once per day (n=30) over 8+/-2 h. Imiquimod 5% cream was safe in both treatment groups. However, the 3 times/week regimen was better tolerated with a lower incidence of local skin reactions. In both groups, the 2 most frequently reported local skin reactions were erythema and erosion; they were more severe with the once-daily dosing. The most frequently reported application site reactions were burning, pruritus and irritation or pain (once-daily patients only). Total clearance was achieved in 62% of the patients in the 3 times/week group and by 57% in the once-daily group. Thus, imiquimod 5% cream administered 3 times/week was the optimal dosing regimen in the treatment of penile warts in uncircumcised men.
authors.affiliation: Department of Dermatology and Venereology, University of Magdeburg, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Gollnick
authors.forename: R
authors.initials: R
authors.lastname: Barasso
authors.forename: U
authors.initials: U
authors.lastname: Jappe
authors.forename: K
authors.initials: K
authors.lastname: Ward
authors.forename: A
authors.initials: A
authors.lastname: Eul
authors.forename: M
authors.initials: M
authors.lastname: Carey-Yard
authors.forename: K
authors.initials: K
authors.lastname: Milde
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000634:Aminoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D003218:Condylomata Acuminata / Q000188:drug therapy*; D004890:Erythema / Q000139:chemically induced; D005602:France; D005858:Germany; D006801:Humans; D000077271:Imiquimod; D007369:Interferon Inducers / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D010146:Pain / Q000139:chemically induced; D010409:Penile Diseases / Q000188:drug therapy*; D011537:Pruritus / Q000139:chemically induced
chemical_list: D000634:Aminoquinolines; D007369:Interferon Inducers; D000077271:Imiquimod